Mitomycin C
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-02559 |
| CAS | 50-07-7 |
| Molecular Weight | 334.33 |
| Molecular Formula | C15H18N4O5 |
| Purity | Assay ≥ 970 mg/g Mitomycin |
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-02559 | 250 mg | $299 | In stock | |
| BBF-02559 | 1 g | $524 | In stock |
Online Inquiry
Add to cartCapabilities & Facilities
Fermentation Lab
4 R&D and scale-up labs
2 Preparative purification labs
Fermentation Plant
Semi pilot, pilot and industrial plant 4 Manufacturing sites 7 Production lines at pilot scale 100+ Reactors of 30-4000 L; 170+ reactors of 20 KL-30 KL; 24+ reactors of >100 KL 2 Hydrogenation reactors (200 L, 4Mpa and 1000L, 4Mpa)
Product Description
Mitomycin C is a quinone mitomycin antibiotic produced by Str. caespitosus NRRL 2564. It has antibacterial, antimycobacterial and antiviral activities. And it has an inhibitory effect on tumors.
- Specification
- Properties
- Reference Reading
- Price Product List
- QC Data
| Synonyms | Mitiromycin E; Mutamycin; Ametycine; Zilimeisu |
| Storage | 2-8°C |
| IUPAC Name | [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate |
| Canonical SMILES | CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N |
| InChI | InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1 |
| InChI Key | NWIBSHFKIJFRCO-WUDYKRTCSA-N |
| Source | Streptomyces sp. |
| Appearance | Blue-violet, crystalline powder |
| Application | Mitomycin C is also available as a a 4% mixture in NaCL. See "Mitomycin C+NaCL" Sample CoA |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria; mycobacteria; neoplastics (Tumor); viruses |
| Boiling Point | 581.8°C at 760 mmHg |
| Melting Point | 360°C |
| Density | 1.56 g/cm3 |
| Solubility | It is freely soluble in DMF, slightly soluble in water and in methanol, and very slightly soluble in ethanol (99.5). |
1. Mitomycin C: a clinical update
W T Bradner Cancer Treat Rev . 2001 Feb;27(1):35-50. doi: 10.1053/ctrv.2000.0202.
Mitomycin C was reviewed in this journal 25 years ago and an update of its clinical usefulness is appropriate. The current review is based on representative publications covering clinical trials performed throughout the world. Single agent activity in each of the major neoplastic diseases has been reassessed when possible and the most important combinations evaluated. It is concluded that mitomycin C has a definite place in the treatment of localized bladder cancer, is active, but needs to be redefined, in the context of newer regimens for breast, head and neck, and non-small cell lung cancers, is active in, but is being displaced by, other drugs in cervical, gastric and pancreatic cancers, and is probably no longer of therapeutic value in colon cancer. It is also recognized that as many newer treatments have clinical success, the therapeutic role of mitomycin C will require continuing re-investigation.
2. [Mitomycin C and excimer laser]
Maria Cristina Ventura Leoratti, Anelise Dutra Wallau, Mauro Campos Arq Bras Oftalmol . 2005 Nov-Dec;68(6):867-72. doi: 10.1590/s0004-27492005000600031.
Mitomycin C is an antimetabolite agent that blocks DNA and RNA replication and protein synthesis. It has been used in several ophthalmologic areas, and recently as a modulator of corneal wound healing in excimer laser surgeries. A single application of mitomycin C during surface corneal photoablative surgery seems a safe and efficient therapeutic option for eyes with corneal opacity and/or as prophylaxis in eyes with high risk for corneal opacity development. The use of this drug in photoablative surgery should be cautious until long-term safety results have been reported. The present text presents a review about corneal wound healing with the use of mitomycin C.
3. Topical versus interlesional mitomycin C in auricular keloids
Yasser Mandour, Mostafa Gomaa, Essam Akl, Esmael Mofty, Hossam Bake, Ahmed Elrefae, Eman Ramadan Acta Otorrinolaringol Esp (Engl Ed) . 2021 Sep-Oct;72(5):280-287. doi: 10.1016/j.otoeng.2020.06.006.
Background:The Keloid is an elevated fibrous scar that may extend beyond the borders of the original wound.Object:To compare between topical and intralesional mitomycin C in the treatment of auricular keloids.Patients and methods:Prospective randomized study in which 40 patients with auricular keloids were included. The patients were divided into 2 groups, Group I included 32 patients who underwent topical mitomycin C application after the surgical removal of the auricular keloids, while Group II included 8 cases who underwent intra-lesional injection of mitomycin C after surgical removal of the auricular keloids.Results:The two groups showed no significant difference regarding patient or lesion criteria (p>.05). VSS decreased significantly from 10.63 and 11.0 down to 1.38 and 3.0 after treatment in the topical and intra-lesional groups respectively (p<.001). However, greater improvement and satisfaction was detected in the topical group.Conclusion:Both topical and intra-lesional mitomycin C injection are effective methods in managing auricular keloids. However, better VSS scores and patient satisfaction are reported with topical administration.
| BBF-03908 | Miltefosine | Inquiry |
| BBF-02800 | DB-2073 | Inquiry |
| BBF-03827 | Polymyxin B sulphate | Inquiry |
| BBF-03774 | Cephalosporin C Zinc Salt | Inquiry |
| BBF-03756 | Amygdalin | Inquiry |
| BBF-03781 | Resveratrol | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
